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Abstract
Background data: The prevalence of steatosis and hepatitis-related liver cirrhosis is dramatically
increasing together worldwide. Cirrhosis and, more recently, steatosis are recognized as a clinically
important feature that influences patient morbidity and mortality after hepatic resection when
compared with patients with healthy liver.
Objective: To review present knowledge regarding how the presence of cirrhosis or steatosis can
influence postoperative outcome after liver resection.
Methods: A critical review of the English literature was performed to provide data concerning
postoperative outcome of patients presenting injured livers who required hepatectomy.
Results: In clinical studies, the presence of steatosis impaired postoperative outcome regardless
the severity and quality of the hepatic fat. A great improvement in postoperative outcome has been
achieved using modern and multidisciplinary preoperative workup in cirrhotic patients. Due to the
lack of a proper classification for morbidity and a clear definition of hepatic failure in the literature,
the comparison between different studies is very limited. Although, many surgical strategies have
been developed to protect injured liver surgery, no one have gained worldwide acceptance.
Conclusion: Surgeons should take the presence of underlying injured livers into account when
planning the extent and type of hepatic surgery. Preoperative and perioperative interventions
should be considered to minimize the additional damage. Further randomized trials should focus
on the evaluation of novel preoperative strategies to minimize risk in these patients. Each referral
liver center should have the commitment to report all deaths related to postoperative hepatic
failure and to use a common classification system for postoperative complications.
Liver surgery is the only curative treatment of patients
with liver tumors [1-3]. Developments in surgical tech-
niques and advances in the management of critical
patients have increased the number of potential candi-
dates for surgery [4]. High-volume centers have convinc-
ingly reported a dramatic decrease in perioperative
mortality after liver resection over the past two decades
[5,6]. Even zero mortality can be achieved with systematic
preoperative patient selection [1].
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As a result of better postoperative outcome, indications
for liver surgery and the extent of liver resection have
expanded and currently major liver resections are rou-
tinely performed despite the presence of underlying liver
disorders [6]. While major hepatic resection (≥ 3 liver seg-
ments) can be safely performed on healthy livers, the risk
of such resection in patients with underlying hepatic dis-
ease remains unclear. The available literature shows a
great dispersion in postoperative mortality rates associ-
ated with liver failure after hepatic surgery in either sick or
healthy liver [7,8]. Moreover, the lack of a clear definition
of postoperative liver failure, the use of different classifi-
cation systems to assess postoperative complications and
the absence of reliable parameters to estimate the remnant
liver volume necessary to avoid hepatic failure makes the
interpretation of the literature a difficult challenge
[7,9,10].
A potentially increased risk of impaired postoperative
recovery has been suggested for patient with cirrhosis [11]
and recently, also for those with liver steatosis [12]. The
objective of this review is to present the knowledge regard-
ing how the presence of cirrhosis or steatosis can influence
postoperative outcome after liver resection.
Steatotic livers
By definition hepatic steatosis is characterized by an accu-
mulation of lipids in the liver and is related to a spectrum
of etiologic features such as obesity, diabetes, excessive
use of alcohol, and a variety of drugs and toxins [13,14].
Fatty accumulation is considered pathologic when the
hepatic fat content, consisting mainly of triglycerides,
exceeds 5% of the actual wet weight of liver [15].
In a retrospective study of a large series of hepatic resec-
tions covering a decade (1991–2001), liver steatosis was
found to be the most common underlying hepatic abnor-
mality [6]. Even though the global prevalence has yet to
be evaluated, studies reported prevalence of 10% to 20%
in lean population, 60% to 74% among the obese (i.e.
body-mass index ≥ 30 kg/m2) and over 90% in the mor-
bidly obese (i.e. body-mass index ≥ 40 kg/m2) [16-20].
Approximately, 3% of lean children are affected and the
prevalence increases up to 53% among obese children
[13,21]. Incidence of steatohepatitis ranges from 3% in
lean population, to 18% among obese to almost 50% in
morbidly obese individuals. In patients with steatohepati-
tis, the risk to develop cirrhosis is 10% to 30% and is asso-
ciated with a decreased 5- and 10-year survival of 67% and
59%, respectively [15]. Moreover, the prevalence of stea-
tosis and steatohepatitis is expected to dramatically
increase in the near future due to increasing obesity
among the Western population.
Diagnosis
Steatosis is usually an incidental finding and hepatomeg-
aly is often the only finding on physical examination.
Despite widespread clinical use of imaging methods,
ultrasound, computed tomography, or magnetic reso-
nance imagining can only to some extent detect the degree
of steatosis. Saadeh et al demonstrated the limitation of
radiological modalities in a study where only steatosis
>25–30% could be reliably detected radiologically [22].
In addition, none of these modalities was able to either
distinguish the grading or the type of liver fat or to detect
the individual pathologic features important to establish
steatohepatitis such as necro-inflammatory changes,
hepatocyte ballooning, and fibrosis [23].
There is consensus that the gold standard of diagnosis is =
2 liver biopsies, as a single biopsy can result in substantial
misdiagnosis and staging inaccuracies [24]. However, due
to the risk of fatal bleeding after liver biopsy (0.4%), it is
not routinely performed in patients without apparent
complicated liver disease [25]. A uniform quantitative
grading for steatosis and steatohepatitis has been sug-
gested, combining the identified key pathologic features
[26]. Besides quantitative grading, steatosis can be classi-
fied qualitatively into microvesicular and macrovesicular
forms. Most frequent is the macrovesicular one, and is fre-
quently associated with obesity, non-insulin-dependent
diabetes, some dyslipidemias, and alcohol abuse. Micro-
vesicular steatosis is usually related to more acute condi-
tions such as acute viral infections, metabolic disorders,
and various toxins but also to acute fatty liver of preg-
nancy. The histopathologic features of steatosis are evalu-
ated in preoperative needle biopsies or operative wedge
specimens that are frozen and/or deparaffinized. The
staining methods currently used are hematoxylin and
eosin with which the fatty changes are assessed by consid-
ering the non-stained regions. In addition, specific fat
stains such as Oil Red O and Sudan III are used. However,
there are several problems in clinical application of these
staining methods. The conventional techniques poten-
tially underestimate the extent of fatty infiltration as they
fail to identify microvesicular forms of steatosis [27]. Also
the fat specific stains have pitfalls, for example, in Oil Red
O-stained liver tissue, the quality and quantity of the
staining are highly operator-dependent and false-positive
results or overestimation of the severity are possible
because of unspecific sinusoidal staining [28].
Associated Clinical Conditions
Patients with nonalcoholic fatty liver disease have an
increased prevalence of non-insulin-dependent diabetes,
but the actual role of diabetes in postoperative recovery is
unclear as studies report contradictory results. Non-insu-
lin-dependent diabetes was identified as independent and
significant variable predicting major postoperative com-Patient Safety in Surgery 2008, 2:8 http://www.pssjournal.com/content/2/1/8
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plications in a cohort of 209 patients undergoing liver
resection [29]. However, contrary to this study, a study
including 525 diabetic and non-diabetic patients requir-
ing hepatectomy, reported no difference in perioperative
morbidity or mortality and no effect was observed in
long-term prognosis [30]. Although the impact of diabe-
tes on postoperative complications remains unclear, an
increased rate of wound infections was reported in an
impressive cohort of over 20,000 patients [31]. From the
analysis of a large database, was concluded that a subset
of diabetic patients having steatosis in the analysis of the
liver specimen, poorly tolerate major liver resection [32].
Thus, when contemplating major hepatectomy in patients
with diabetes mellitus, surgeons should be aware that the
presence of diabetes mellitus may lead to higher incidence
of hepatic failure postoperatively.
Obesity is crucially linked with steatosis [14]. In the past,
obesity has been also linked to increased perioperative
technical complications leading to prolonged postopera-
tive recovery. However, Dindo et al prospectively investi-
gated a cohort of 6336 patients undergoing elective major
surgery and found no increase in postoperative morbidity
and mortality between obese and non-obese, not even in
morbidly obese patients [33]. However, the authors did
not discriminate patients who underwent exclusively liver
surgery. Unfortunately, reports referred to perioperative
outcome of obese patients requiring hepatectomy are
scarce in the literature.
In contrast to general obesity, body fat accumulation
(subcutaneous or intraabdominal) has been reported to
be independently associated with postoperative morbid-
ity in a prospective study of 139 patients who underwent
gastric or colorectal cancer surgery [34].
Post-Operative Complications
Only a few studies have focused on liver steatosis as a risk
factor for postoperative complications after liver resection
(Table 1). However, there are some general problems in
the reporting of these studies. The histopathology meth-
ods for diagnosis of steatosis are not frequently, if ever,
mentioned. So, the reliability of diagnosis of steatosis
remains uncertain, rendering the comparison of the
results difficult. Uniform grading together with a more
detailed description of the staining methods used and the
number and sort of biopsies taken are important to com-
pare different studies [15]. In the absence of a uniform
classification system accepted by most to better stratify
morbidity by severity, scarce data is reported concerning
the incidence of major complication rate after liver resec-
tion in steatotic patients. Finally, mortality is usually
assessed as in-hospital mortality or 60 days mortality after
operation, and there are no studies evaluating 5- or 10-
year survival of steatotic patients after surgey.
In 1998, Behrns et al evaluated in a retrospective study of
135 patients, the safety of major resection in patients with
hepatic steatosis [35]. They reported an increased postop-
erative mortality, morbidity, and blood transfusion rates
together with longer operative time in the presence of
steatosis of ≥ 30%. Belghiti et al, in a large database
including 478 liver resections, detected the presence of
hepatic steatosis ≥ 30% in 37 (7.7%) patients, and they
demonstrated that steatosis was an independent risk fac-
tor for postoperative complications but not for mortality
[5]. In the analysis of a cohort of 1803 liver resections, the
histological analysis demonstrated that only 55% of the
liver specimens had normal parenchyma and 18% had
liver steatosis [6]. In contrast, the presence of steatosis was
not a risk factor for postoperative outcome after hepatec-
tomy. Later, Kooby et al reviewed the above-mentioned
cohort to perform a case-matched study involving 325
steatotic patients compared with 160 with normal liver
Table 1: Reported studies focus on postoperative outcome after liver resection of patients with steatotic livers.
Authors Year Center Grading of 
steatosis (%)
Number of 
patients
Overall 
Complication (%)
P value Mortality (%) P value
Behrns et al (35) 1998 Mayo Clinic. Rochester, USA. None 72 10 NA 3 NA
Mild (<30) 56 14 7
Marked (≥ 30) 7 29 14
Belghiti et al (5) 2000 Hopital Beaujon. Paris, France. None 441 8 0.003 1 0.5
Steatosis (≥ 30) 37 22 0
Jamargin et al (6) 2002 MSKCC. New York, USA. None 1275 48 0.197 3.9 0.309
Steatosis (≥ 30) 380 44 2.8
Kooby et al * (36) 2003 MSKCC. New York, USA. None 160 35 <0.01 3.1 0.29
Mild (<30) 223 48 3.6
Marked (≥ 30) 102 62 5.9
Mc Cormack et al * (12) 2007 Swiss HPB Center. Zurich, Switzerland. None 58 @ 6.9# 0.001 1.7 0.21
Steatosis (≥ 10) 58 @ 27# 8.6
NA: Not Available; * Case matched analysis; # Referred only to major complication rate using Dindo et al classification (10); @ Only major liver resection were analyzed (≥ 3 
liver segments)Patient Safety in Surgery 2008, 2:8 http://www.pssjournal.com/content/2/1/8
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who were matched according to age, co-morbidities, and
the extent of resection [36]. Interestingly, they showed
that steatosis was a predictor of postoperative complica-
tions, but mainly due to minor complications. Major
postoperative complications, eg, requiring major thera-
peutic intervention or mortality, were not affected by the
presence of steatosis. To note, information regarding the
presence of concomitant risk factors, such as nutritional
parameters, kidney function and cholestasis, were not
included in this analysis. Furthermore, the histologic
analysis did not differentiate between the two types of
liver steatosis or other histological features such as steato-
hepatitis or fibrosis. Therefore, we decided to investigate
the influence of the quantitative and qualitative analysis
of steatosis in postoperative outcome after major liver
resection [12]. In our study, each patient with liver steato-
sis was matched with a similar patient with normal liver
who required major hepatectomy according to the follow-
ing variables: age, gender, ASA (American Society of
Anesthesiologists) score, diagnosis, extent of hepatec-
tomy, and the need of bilio-enteric bypass. We found that
steatosis was the most significant preoperative risk factor
for postoperative complications and should be consid-
ered for the planning of a major liver resection. Interest-
ingly, neither the type nor the grading of liver steatosis
influenced postoperative outcome after major hepatec-
tomy. A novel finding in this study was that the presence
of preoperative jaundice in a steatotic liver was an inde-
pendent risk factor for mortality after surgery. Conse-
quently, efforts should be made either to postpone
surgery until normalization of bilirubin or to minimize
the extent of liver resection in those patients (e.g., eco-
nomic hepatectomy combined with ablation therapies,
two-stage hepatectomy, etc).
Cirrhotic livers
Reduction of postoperative morbidity and mortality is
still a great challenge in cirrhotic patients. Today, an
improvement in perioperative outcome of cirrhotic
patients undergoing liver surgery has been achieved as a
result of a continuous advance in preoperative imagining,
surgical technique, anesthesia and critical care unit man-
agement. However, probably the most important factor
for better outcome in cirrhotic patients is based in a care-
ful and accurate patient selection. Preoperative patient
selection must be performed by multidisciplinary teams
with special focus in hepatic diseases working in referral
high-volume center [37].
Pre-operative management
Although blood tests intended to evaluate preoperative
hepatic function in cirrhotic patients requiring liver resec-
tion, these techniques frequently underestimate the
underlying liver disease [38]. In an attempt to solve this
problem, many different methods have been used to eval-
uate hepatic functional reserve. Among all, the Child-
Pugh clinical score is the most validated and used method
for cirrhotic patients. Major hepatic resections are safely
performed in patients scored as Child- Pugh A but this
classification failed to be an adequate predictor of the
extent of the liver resection that could be safely per-
formed. In contrast, patients classified as Child- Pugh B
and C have unacceptable morbidity and mortality risks
and therefore are not suitable for major liver resections
[39].
Several methods have been proposed to evaluate hepatic
function prior to liver surgery including those based on
liver perfusion and biliary excretion (e.g. indocyanine
green), on microsomal or cytosolic function (e.g. ami-
nopyrine breath test, galactosyl elimination capacity) and
on functional imaging (e.g. 99m-Tc-galactosyl-human
serum albumin scintigraphy) [8,40-43]. Redealli et al
established in a prospective study that a galactosyl elimi-
nation capacity < 4.0 mg/min/Kg is a strong predictor of
complications after hepatic surgery in patients with HCC
and liver cirrhosis [41]. Among all, the most commonly
used is the indocyanine green (ICG) clearance test widely
used in eastern countries for cirrhotic patients with hepa-
tocellular carcinoma requiring liver surgery [40,44]. The
ICG clearance test evaluated the retention rate of the sub-
stance after 15 minutes wich is actively transfer into the
hepatic parenchyma, which seems to be the only mecha-
nism involved in metabolism. Finally it is secreted into
the bile [8]. The ICG test values are determined by blood
sampling or as the percent retention determined by
pulsed spectrophotometry in a similar fashion to an oxy-
gen saturation monitor [45]. However, the grater limita-
tion of this test is the variation of results associated with
changes in hepatic blood flow. While patients classified as
Child-Pugh score A with ICG retention rate <14 % are eli-
gible for large resection, those with results between 15%
and 20% are only suitable for limited resections [46].
Some authors combined the results of Child-Pugh score,
ICG retention rate at 15 minutes and other biochemical
results to define the magnitude of resection, or to decide
the use of a preoperative portal embolization to achieve a
compensatory hypertrophy of the future liver remnant
[1,47]. For example, Wo et al sustained that in patients
with ICG retention rate >50%, total bilirubin >4 mg/dl or
protrombine time <75%, surgery should not be per-
formed [48]. Taking these parameters into account there
have been low mortality rates attributed to liver failure
and acceptable morbidity [46,49,50].
However, the grater limitation of these tests is the varia-
tion of results associated with changes in hepatic blood
flow and others entities affecting hepatic function leading
some authors to discuss the accuracy of this methodPatient Safety in Surgery 2008, 2:8 http://www.pssjournal.com/content/2/1/8
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[51,52]. For example, Herold et al found unequal results
when comparing tests for hepatic metabolism as galacto-
syl elimination capacity or aminopyrine breath test with
ICG test in patients affected with chronic hepatic diseases
[42]. Currently, there is no functional test capable to
define on its own the degree of functional reserve and the
extent of resection. Therefore, a general algorithm used to
evaluate the functional liver reserve in patients with
chronic hepatitis or cirrhosis in many centers include clin-
ical evaluation in the search of co-morbidities, blood test-
ing including platelet count and coagulation studies, ICG
test, hepatic volume measured by imaging and Child-
Pugh classification [44,47].
The presence of severe portal hypertension is an accepted
contraindication for liver resection [53]. To exclude this
situation, the grade of portal hypertension must be evalu-
ated during preoperative work-up with platelet count,
measurement of spleen by imaging studies and endos-
copy to assess the presence of esophagus varices [44]. In
case of esophagic varices grade III, the patient must be
endoscopically treated before surgery [54]. Some authors
recommended the systematic measurement of portal pres-
sure gradient to select patients more accurately [11,53].
Bruix et al demonstrated that a portal pressure gradient
higher than 10 mmHg was associated with increased mor-
bidity and reduced survival [53]. Furthermore in those
with associated high bilirubin mortality was increased
[11]. As a consequence, a systematic preoperative meas-
urement of portal pressure gradient has been used in
many centers to better select cirrhotic patients with liver
tumors [11,53]. Others proposed to delay or avoid hepa-
tectomy in virus related cirrhotic patients with high
hepatic transaminases to reduce postoperative mortality
[47].
Another important factor to take into account when
hepatic regeneration is desired is cholestasis. In this spe-
cific situation, most authors agree to perform a preopera-
tive biliary percutaneous drainage of the hemi-liver that
will remain after surgery [55]. Nevertheless, many varia-
bles such as the type and etiology of the underlying liver
disease, the extent and location of the lesions, make the
experience of the treating team of primary importance to
define the extent of the liver resection in each particular
patient [6]. Co-morbidities tend to start or enlarge periop-
erative complications, so it is sensitive to achieve ASA
score I-II prior to surgery because it reduces risk [47].
Moreover, there are entities related to cirrhotic status that
can be resolved during surgery to prevent further compli-
cations. For example, some authors recommended to per-
form splenectomy during hepatectomy to reduce
postoperative medical complications in patients with
severe hyperesplenism [56,57].
Evidence from liver transplant suggests that the donor
graft volume must represent ≥ 0.8% of the total body
weight of the receptor to reduce the risks of acute hepatic
failure [58]. However, the regeneration of chronically ill
liver is not equal than that observed in normal organs
[8,39,59,60], thus surgeons must be extremely cautious
when defining the extent of functional remaining paren-
chyma to avoid postoperative hepatic failure. Makuuchi et
al proposes preoperative right portal vein embolization
(PPVE) as a useful attempt to increase the volume of the
future remaining liver [61]. Azulay et al demonstrated that
resecability can be achieve when PPVE is indicated in cir-
rhotic patients when the estimated future remnant liver
parenchyma ≤40% [62]. When the liver does not regener-
ate after PPVE, most agree that major hepatectomy should
be contraindicated to avoid severe postoperative liver fail-
ure [63]. Today, most authors recommend to perform
PPVE when the remaining liver is ≥ 25–30% of the whole
organ in normal liver and ≥ 40% in injured livers
[40,47,49,62]. In eastern countries, where ICG test is
widely used in cirrhotic patients, PPVE is recommended
when the non-tumoral parenchyma to be removed is ≥
40% of the organ together with ICG test of 10% to 20%
[50].
Post-Operative Complications
A comparative analysis of morbidity and mortality in cir-
rhotic patients undergoing liver surgery is very limited as
a result of the absence of a standard manner to report
postoperative complications. Moreover, most of the stud-
ies involve cirrhotic as well as other patients with different
hepatic disorders such as fibrosis, cholestasis or hepatitis.
Finally, there is no description of severity degree of post-
operative complications and often the cause of death is
not reported (Table 2).
The evolution of hepatic surgery together with the intro-
duction of novel surgical strategies and modern transec-
tion techniques has led to a dramatic reduction in
mortality rates from 10–32% [7,64,65] to current series
displaying mortality rated of <8% (Table 2). Although
post-operative hepatic failure has also been reduced to
<5% [46,50,66], most of the different surgical teams eval-
uate failure in their own fashion.
Many liver surgeons advocated to the conventional
approach for the surgical treatment of these patients to
reduce hemorrhagic complications. However, some
authors have suggested that the laparoscopic approach
when feasible can reduce complications related to the
abdominal wall or ascitis [67-69]. The use of systematic
drainage of abdominal cavity after hepatic surgery in cir-
rhotic liver has no proven benefits [70,71] and there is
also an association with infections, abdominal wall com-
plications and prolonged hospital stay [72].Patient Safety in Surgery 2008, 2:8 http://www.pssjournal.com/content/2/1/8
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Protective strategies in injured livers
Various approaches have been proposed to improve the
poorer postoperative outcome of patients with steatosis or
cirrhosis after liver surgery. A positive correlation between
preoperative liver function, operative time, blood transfu-
sion requirement and postoperative morbidity has been
demonstrated [48]. In addition, the extent of blood loss
by itself is responsible for short and long term complica-
tions [73]. Consequently, inflow occlusion by clamping
of the portal triad (Pringle maneuver) has been used since
the early 20th century to minimize blood loss during
transection of the liver parenchyma in cirrhotic [74] and
non-cirrhotic patients [75]. A randomized study con-
firmed the safety of using inflow occlusion during transec-
tion even in cirrhotic livers [76]. This strategy is
particularly effective in preventing blood loss but only
when associated with low central venous pressure. Ante-
rior approach as a surgical tactic for broad lesions that
affect right liver and inhibits its mobilization has proved
to be also effective to reduce intra-operative bleeding [77].
Low central venous pressure anesthesia, inflow and/or
outflow vascular control, novel transection or coagulation
devices are intended all to reduce such loses [38,50].
A recent randomized controlled trial showed that liver
transection under inflow occlusion with the clamp crush-
ing technique is associated with lower blood loss and
reduced requirement for perioperative transfusions, than
resection performed with more sophisticated transection
devices claimed to enable safe surgery without the need
for inflow occlusion [78]. However, the Pringle maneuver
induces ischemic injury in the remnant liver, which is
directly related to the duration of inflow occlusion and
associated with increased morbidity and mortality [79].
The use of total vascular exclusion during hepatic resec-
tion, greatly reduces blood loss, and also ulterior liver
regeneration is affected by ischemic organ injury suffered
during this process [5]. Two protective strategies such as
intermittent clamping (IC) and ischemic preconditioning
(IP) intended to reduce ischemic injury and bleeding,
however most available clinical data referred to non-cir-
rhotic patients [67,74,80-82].
There is growing evidence that liver steatosis is associated
with reduced outcome after hepatic resection [12]. Since
in animal models was observed that steatotic livers poorly
tolerate warm ischemia during hepatectomy, many sur-
geons advocated to develop protective strategies against
ischemic injury of these livers [83]. However, animal
models applied in experimental studies to protective strat-
egies have all biases precluding the extrapolation of
results to the clinical situation [15,83]. The development
of clinically relevant experimental models is also hindered
by the spectrum of patients with different etiologic factors.
Different etiologic backgrounds lead to different forms of
steatosis combined with a range of pathologic features
unique to some etiologic factors. Furthermore, the clinical
significance of the type and extent of steatosis is not clear
as larger cohort studies applying uniform diagnostic crite-
ria are missing. In two clinical randomized trial compar-
ing IP or IC versus continuous clamping the highly
protective effect of both strategies in steatotic livers was
clearly stated [84,85]. In a recent study, the protection
conferred by IC was fully preserved in steatotic livers, even
if >30% of steatosis was present, while this protective
effect was weaker in the IP group [81]. These data may
imply that IC should be preferred in patients with severe
steatosis and expected prolonged ischemia time. How-
ever, more research is needed in this field of surgery as the
prevalence of steatosis and hepatitis-related liver cirrhosis
is dramatically increasing together worldwide.
Conclusion
Cirrhosis and, more recently, steatosis are recognized as a
clinically important feature that influences patient mor-
bidity and mortality after hepatic resection when com-
pared with patients with healthy liver. In the last years,
steatosis has become a major concern as its prevalence is
Table 2: Reported postoperative outcome of cirrhotic patients undergoing liver resection.
Authors Year Number of patients Cirrhosis (%) Overall Complication (%) Liver Failure (%) 30-day Mortality (%)
Midorikawa et al (50) 1999 173 65 67.6 0& 0
Fong et al (86) 1999 154 64.9 45 5 4.5
Torzilli et al (49) 1999 107 59.8 26.2 NA 0
Belghiti (5) 2000 253 94.5 NA NA 9.5
Takano et al (87) 2000 300 90 $ 26 * NA 4
Zhou et al (66) 2001 1000 88.8 NA 0.5 1.5
Poon et al (46) 2002 206 100 34.9 4.4 5.3#
Grazi et al (88) 2003 443 69.5 37 NA 5.9 #
The et al (89) 2005 82 100 NA 11 16
NA: Not Available; $ series including cirrhosis and other hepatic disorders; * Referred to major complication; &Hepatic insufficiency defined as the 
presence of both prolonged jaundice (total bilirubin level >3 mg/dL) and encephalopathy; # Hospital mortality defined as any death occurring during 
the same hospital admission of the hepatic resectionPatient Safety in Surgery 2008, 2:8 http://www.pssjournal.com/content/2/1/8
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closely linked to obesity, an epidemic disease in Western
countries. There is an urgent need for reliable noninvasive
methods to detect steatosis and related pathologic fea-
tures preoperatively.
Surgeons should take the presence of injured livers into
account when planning the extent and type of hepatic sur-
gery. Preoperative and perioperative interventions should
be considered to minimize the additional damage. The
future goal should be to use by consensus a proper classi-
fication for morbidity and hepatic failure in liver surgery
to compare results between reference centers. These cent-
ers should have the commitment to report all deaths
related to hepatic failure after surgery.
On choosing a standard of care and treatment for patients
with chronic hepatic disease there are no fixed strategies.
Each team based on current evidence should decide the
best algorithm according to each patient to reach similar
rates of morbidity and mortality than those of patients
with healthy liver. Further randomized trials should focus
on the evaluation of novel preoperative strategies, such as
short-term intensive medical treatment of hepatic steato-
sis and preoperative portal vein embolization, to mini-
mize risk in these patients.
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